Company Overview and News

 
Cosmopolitan International Will Invest In An US Entertainment Content Development And Production Company

2017-06-02 marketwired
HONG KONG, CHINA--(Marketwired - Jun 1, 2017) - Cosmopolitan International Holdings Limited ("Cosmopolitan") (HKSE: 0120) is pleased to announce, Cosmopolitan International Investments Limited ("CIIL"), a wholly-owned subsidiary of Cosmopolitan, entered into the Term Sheet with the Potential Target Company and its chief executive officer (the "CEO") (independent third parties) in relation to possible investment in the Potential Target Company.

 
Century City Group intends to cooperate on a property development project in New York, and Regal REIT will acquire the iclub Ma Tau Wai Hotel in To Kwa Wan

2017-05-24 marketwired
HONG KONG, CHINA--(Marketwired - May 24, 2017) - Century City International Holdings Limited ("Century City") (HKSE: 355), Paliburg Holdings Limited ("Paliburg" (HKSE: 617) and Regal Hotels International Holdings Limited ("Regal") (HKSE: 78) are pleased to announce the following transactions:

 
New Hong Kong airport hotel will profit from mainland Chinese tourism rebound, says Regal

2017-02-07 scmp
Regal Hotels Group acquired the luxury hotel project at Hong Kong International Airport based on the belief that mainland Chinese tourists are returning to the city, a company executive said.

 
The hotel heiress taking on Disney, one cute puppy at a time

2016-06-08 business.asiaone
Poman Lo has a life lesson for any young person weighing up whether to work in the family business; joining the firm doesn't have to mean giving up your personal career dreams.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

12h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...